Evaluation of Colorectal Cancer Screening Strategies in China：A Prospective Randomized Trial

Shandong University0 sites20,000 target enrollmentJuly 2022

Overview

A large-scale randomized controlled trial was conducted to compare different colorectal neoplasms screening strategies in China.

Registry

clinicaltrials.gov

Start Date

July 2022

End Date

December 2023

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Shandong University

Responsible Party

Principal Investigator

Yanqing Li

Vice President of Qilu Hospital

Shandong University

•Previous colorectal cancer
•Previous colorectal resection
•Previous received cancer-related treatment (except non-melanoma skin cancer)
•Colonoscopy, sigmoidoscopy, CT colonoscopy, and barium enema were performed within 5 years
•Fecal occult blood or fecal DNA was performed within one year
•Symptoms of lower digestive tract diseases requiring colonoscopy include: (1) rectal bleeding occurred more than once in the past 6 months, (2) recorded iron deficiency anemia, and (3) recorded significant weight loss within 6 months (\> 10% of baseline weight - Suffering from other diseases that affect the benefit of screening or intolerance to colonoscopy (for example, severe pulmonary disease, end-stage renal disease, end-stage liver disease, severe heart failure or recently diagnosed cancer, except non-melanoma skin cancer)